Work

Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors

Year: 2015

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-15-c49

Authors: Funda Meric-Bernstam, Angela DeMichele, Melinda L. Telli, Pamela Munster, Keith W. Orford, George D. Demitri, Gary K. Schwartz, Othon Iliopoulos, James W. Mier, Taofeek K. Owonikoko, Mark K. Bennett, Manish R. Patel, Jeffery R. Infante, James J. Harding

Institutions: The University of Texas MD Anderson Cancer Center, University of Pennsylvania, Stanford University, University of California, San Francisco, Calithera (United States), Dana-Farber Cancer Institute, Columbia University Irving Medical Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Emory University, Sarah Cannon, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2365407196

Cites:

Cited by: 8

Related to: 10